Contract Manufacturing, General

Jim Miller, President of PharmSource, spoke with Pharmaceutical Technology about working with CMOs and CDMOs.

A presentation by Jim Miller will offer a detailed review of the contract services landscape.

Is there enough talent to go around?

Market forces may limit the success of CMOs.

The trend of exits from the CMO industry looks to be gaining momentum.

Representatives of contract service organizations that specialize in parenteral drug development and manufacturing describe the evolving trends.

CMOs may find opportunities in alternative expression services.

Traditional project decision-making is compared with a QbD approach.

Increased competition from CMOs in Asia means that Western CMOs need to understand fundamental changes in the market.

With numerous biologics set to come off patent soon and the percentage of new therapeutics based on biomolecules growing, demand for contract manufacturing in the biopharma space is heating up.

A CMO perspective on the CMO-client partnership.

Approvals of new drugs are on an upward swing, but only a few CMOs are benefiting.

Is the contract-only CMO an endangered species?

Key talks from the recent PDA/FDA regulatory conference highlight room for improvement.

Annual survey shows strong growth for service providers and promises to continue into 2013.

The evolving bio/pharmaceutical business model poses risk for CMOs.

Contract service providers should be concerned about the market perceptions of their performance.

Too many players and threats to the main customer base challenge European dose manufacturers.

Patheon is betting the whole is worth more than the sum of the parts in its acquisition of Puerto Rico contract manufacturer Mova.

The blockage in the new product pipeline may be breaking. CROs report increased demand for late-stage development services in their latest round of earnings reports.

Early development services continue to be a sweet spot for contract R&D services. The big question is how soon the impact of early-development candidates will be felt in late development and commercialization.

The contract services industry is fertile ground for the investment banking community this summer.

Data from the 2004 Outsourcing Survey indicate that pharmaceutical companies are spending more on outsourced drug development, but with fewer suppliers.

It's not clear whether contract service providers can deliver the performance improvements and costs savings that drug companies expect from large, long-term, semi-exclusive contracts.

Outsourcing is part of the public debate as politicians seek to explain the lag in job growth despite a recovering economy, and as the Bush administration presses its initiative to "competitively source" more agency activities.

December's Contract Services articles include "Using Virtual Private Networks to Gain Competitive Advantage," by Mark Tuomenoska and "Outsourcing Outlook," by Jim Miller.

November's Contract Services articles include "Outsourcing Xbox Manufacturing," by Heather Hayes, "Outsourcing Outlook," by Jim Miller, and "Quality in Pharmacovigilance," by Brian Edwards and Jeffrey Priem.

The European Union is attempting to reform its current business environment in hopes of restoring its role in the lobal R&D sector.

The author discusses the potential effect on CROs of pending major-pharma mergers and consolidations.

The author examines the concept of evaluating CRO operating performance in today's pharmaceutical industry.